相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study
Akihiko Asahina et al.
JOURNAL OF DERMATOLOGY (2016)
Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
Yoshiya Tanaka et al.
JOURNAL OF RHEUMATOLOGY (2016)
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Mark C. Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PHARMACOKINETICS, SAFETY AND TOLERABILITY OF THE SELECTIVE JAK1 INHIBITOR, ABT-494, IN HEALTHY VOLUNTEERS AND SUBJECTS WITH RHEUMATOID ARTHRITIS
M. -E. Mohamed et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Edward C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Eun Bong Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Janus kinase inhibitors in autoimmune diseases
John J. O'Shea et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
分享论文
